Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

The molecule “T cell immunoreceptor with immunoglobulin and ITIM domain,” or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jin-Hwan, Cai, Mingmei, Grein, Jeffery, Perera, Samanthi, Wang, Hongmei, Bigler, Mike, Ueda, Roenna, Rosahl, Thomas W., Pinheiro, Elaine, LaFace, Drake, Seghezzi, Wolfgang, Williams, Sybil M. Genther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577118/
https://www.ncbi.nlm.nih.gov/pubmed/33117369
http://dx.doi.org/10.3389/fimmu.2020.573405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577118/
https://www.ncbi.nlm.nih.gov/pubmed/33117369
http://dx.doi.org/10.3389/fimmu.2020.573405

Ejemplares similares